List of Excipients in Branded Drug TERIFLUNOMIDE

« Back to Dashboard

Generic Drugs Containing TERIFLUNOMIDE

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	teriflunomide	0115-1565	CELLULOSE, MICROCRYSTALLINE
Amneal Pharmaceuticals of New York LLC	teriflunomide	0115-1565	FD&C BLUE NO. 2
Amneal Pharmaceuticals of New York LLC	teriflunomide	0115-1565	FD&C RED NO. 40

What are the Most Frequently-Used Excipients in TERIFLUNOMIDE?

# Of NDCs	Excipient
19	CELLULOSE, MICROCRYSTALLINE
2	COTTONSEED OIL
1	CROSCARMELLOSE SODIUM

Teriflunomide Excipient Strategy and Commercial Opportunities

Last updated: October 20, 2026

Teriflunomide is a small-molecule, once-daily oral immunomodulator marketed in the United States as Aubagio and available from multiple generic manufacturers. The commercial opportunity is concentrated in low-cost, robust immediate-release tablets, differentiated excipient systems that improve dissolution and manufacturability, and geographic markets where generic substitution remains incomplete. The principal technical challenge is managing teriflunomide’s low aqueous solubility without adding unnecessary formulation complexity.

What is the formulation profile of teriflunomide?

Teriflunomide is the active ingredient in Aubagio tablets used for relapsing forms of multiple sclerosis. The FDA-approved strengths are 7 mg and 14 mg, administered once daily [1].

Attribute	Teriflunomide implication
Dosage form	Immediate-release film-coated tablet
Strengths	7 mg and 14 mg
Route	Oral
Dosing frequency	Once daily
Therapeutic category	Immunomodulator for multiple sclerosis
Development type	Small molecule, not a biologic
Generic pathway	Abbreviated New Drug Application, or ANDA
Primary formulation challenge	Solubility and dissolution control
Key commercial requirement	Low-cost, scalable, bioequivalent tablet
Main safety constraints	Hepatotoxicity, teratogenicity, immunosuppression, and long elimination half-life

Teriflunomide is a weakly acidic compound with limited aqueous solubility. Its absorption is adequate in vivo, but dissolution performance remains important for immediate-release tablet development. Formulation work therefore should focus on particle engineering, wetting, dispersion, and tablet disintegration rather than on extended-release delivery.

The reference product contains conventional tablet excipients, including lactose monohydrate, corn starch, hydroxypropyl cellulose, sodium starch glycolate, magnesium stearate, talc, and coating materials. Exact inactive-ingredient composition varies by strength and product presentation [1].

Which excipients are most suitable for teriflunomide tablets?

A conventional diluent-disintegrant-lubricant system is commercially attractive because it minimizes regulatory risk and manufacturing cost.

Excipient function	Candidate materials	Commercial rationale
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Supports tablet weight, flow, and compression
Binder	Hydroxypropyl cellulose, povidone, copovidone, pregelatinized starch	Improves granule strength and content uniformity
Disintegrant	Sodium starch glycolate, crospovidone, croscarmellose sodium	Accelerates tablet breakup and dissolution
Wetting agent	Poloxamer, sodium lauryl sulfate, low-level surfactant systems	Improves contact between drug particles and dissolution medium
Lubricant	Magnesium stearate, sodium stearyl fumarate	Controls ejection force and tooling adhesion
Glidant	Colloidal silicon dioxide, talc	Improves powder flow
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide, iron oxides	Protects the tablet and supports identification
Taste and swallowability	Film coating, mannitol-based blends	Relevant mainly to pediatric or geriatric positioning

Which direct-compression excipients offer the lowest-cost route?

Microcrystalline cellulose combined with crospovidone or croscarmellose sodium is a strong direct-compression platform. It can reduce process steps, eliminate solvent handling, and simplify scale-up. The approach is most suitable when teriflunomide has adequate powder flow and the formulation achieves acceptable content uniformity at the 7 mg strength.

Low-dose formulations create a content-uniformity risk. A small amount of active ingredient must be distributed consistently across a relatively large tablet mass. Excipient particle size, density, segregation tendency, and blending order can materially affect dose uniformity.

Lactose-based systems remain commercially attractive because they are inexpensive and widely accepted in immediate-release tablets. Lactose should be evaluated against teriflunomide for chemical compatibility, especially under elevated humidity and temperature. Mannitol may provide better sensory properties and lower hygroscopicity but generally carries a higher cost.

Are co-processed excipients commercially useful?

Co-processed excipients can improve flow, compressibility, and disintegration without requiring multiple individual excipient adjustments. Useful platforms include:

• Microcrystalline cellulose-silicon dioxide systems for flow and compactibility.
• Lactose-cellulose blends for direct compression.
• Coprocessed mannitol-cellulose systems for low-dose tablets.
• Starch-based systems for rapid disintegration.
• Spray-dried excipient platforms for improved powder handling.

The commercial value is greatest for manufacturers seeking a single validated formulation that can be manufactured at multiple sites. The cost advantage is less clear where commodity lactose, starch, and magnesium stearate already provide acceptable performance.

How can excipients improve teriflunomide dissolution?

The most practical dissolution strategy is to increase wetting and reduce the effective particle-size burden. Options include micronization, wet granulation, spray drying, nanocrystal processing, and amorphous solid dispersion.

Formulation strategy	Expected benefit	Main risk
Micronized drug	Larger surface area and faster dissolution	Powder cohesion, electrostatic behavior, segregation
Wet granulation	Better content uniformity and tablet strength	Possible agglomeration and process complexity
Surfactant-assisted formulation	Improved wetting	Potential impurity, stability, or tolerability concerns
Amorphous solid dispersion	Higher apparent solubility	Physical recrystallization and stability risk
Nanocrystal formulation	Rapid dissolution and potentially lower dose burden	Higher development and manufacturing complexity
Lipid-based system	Improved solubilization	Poor fit with a conventional low-cost tablet
Solid-state salt or cocrystal	Possible solubility improvement	New solid-form IP and regulatory characterization

For a generic immediate-release tablet, micronization plus a conventional disintegrant is likely to offer the best balance of cost, scalability, and regulatory simplicity. Amorphous dispersions or nanocrystals may create stronger technical differentiation but could undermine the low-cost generic business model.

Which disintegrant is preferable?

Crospovidone, croscarmellose sodium, and sodium starch glycolate are all credible candidates. The selection should be based on dissolution robustness across pH conditions, tablet hardness, lubricant sensitivity, and storage humidity.

Sodium starch glycolate can provide strong swelling-driven disintegration but may be sensitive to overcompression or excessive hydrophobic lubrication. Crospovidone often provides rapid wicking and is less dependent on swelling. Croscarmellose sodium can provide a balanced combination of swelling and wicking.

A dual-disintegrant system may improve robustness, but it increases formulation complexity and may provide little commercial value if the reference-product dissolution profile is already easy to match.

What formulation patents protect teriflunomide products?

Teriflunomide patent exposure is primarily relevant to the active ingredient, pharmaceutical compositions, methods of treatment, and manufacturing processes. The reference product’s commercial protection has historically included Orange Book-listed patents and associated Paragraph IV litigation involving generic applicants.

The strategic distinction is important:

1. A patent claiming teriflunomide as a compound can block or delay generic entry broadly.
2. A composition patent may cover a specific dosage form or excipient combination.
3. A method-of-use patent may be relevant only to a labeled indication or dosing method.
4. A process patent may create manufacturing risk without necessarily blocking a non-infringing formulation.
5. A narrow excipient patent may be commercially weak if a generic manufacturer can substitute an alternative excipient system.

Publicly reported Orange Book and litigation records identify teriflunomide/Aubagio patent disputes involving Sanofi and generic applicants. The relevant reference-product patent family includes U.S. Patent No. 7,632,938 and later listed patents associated with the Aubagio product and its use or manufacture [2,3]. Patent scope, terminal disclaimers, pediatric exclusivity, and settlement restrictions must be assessed by jurisdiction and filing date.

Do excipient patents create meaningful barriers?

Excipient patents can matter when they claim a specific combination that solves a measurable problem, such as:

• Improved dissolution under biorelevant conditions.
• Enhanced stability against humidity or oxidation.
• A defined particle-size distribution.
• A particular granulation or coating process.
• Improved content uniformity for a low-dose tablet.
• A solid dispersion or nanocrystal composition.

Their blocking value is usually lower than that of an active-ingredient patent because generic manufacturers can often design around the claim using a different binder, disintegrant, particle-size range, or process.

The strongest excipient-related patent position would combine a narrow but defensible composition claim with comparative data showing superior dissolution, stability, or bioavailability. A patent that merely lists conventional excipients without a demonstrated technical effect is less likely to produce durable market exclusivity.

When does teriflunomide lose exclusivity?

Teriflunomide’s U.S. small-molecule exclusivity has already transitioned from branded exclusivity to generic competition. FDA approved Aubagio in 2012, and the product’s five-year new chemical entity exclusivity period expired in 2017 [1,4].

Generic entry was affected by patent litigation and settlement arrangements involving Sanofi and ANDA applicants. FDA-approved teriflunomide tablets are now available from multiple manufacturers, reducing the commercial value of a conventional copycat product.

Exclusivity factor	Teriflunomide status
New chemical entity exclusivity	Expired
Biologic exclusivity	Not applicable
Pediatric exclusivity	Historically relevant to timing; does not create current biologic-style protection
Orange Book patent risk	Relevant to historical and residual litigation analysis
Generic pathway	ANDA
Current commercial model	Multi-source generic market with price competition

Exact patent expiration dates should be taken from the current FDA Orange Book and patent records because listed patents may include patent-term adjustment, terminal disclaimers, and different claim scopes [2].

What is the FDA regulatory status of teriflunomide?

Teriflunomide is FDA-approved as an oral tablet for adults and pediatric patients aged 10 years and older with relapsing forms of multiple sclerosis [1]. The product is subject to significant labeling requirements related to liver injury, pregnancy, bone marrow effects, infection risk, and accelerated elimination.

These safety requirements affect excipient strategy indirectly. A new formulation should avoid unnecessary excipients that create:

• Additional hypersensitivity concerns.
• Pediatric acceptability problems.
• Novel impurities or extractables.
• Significant changes in absorption.
• Stability failures that could increase impurity exposure.
• Manufacturing variability that complicates bioequivalence.

A standard immediate-release tablet generally offers the cleanest ANDA pathway. A novel delivery system may trigger more extensive comparative studies and create avoidable regulatory questions.

Does teriflunomide have biosimilar risk?

No. Teriflunomide is a chemically synthesized small molecule, not a biologic. Biosimilar approval under the Public Health Service Act does not apply. Competitive products use the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence rather than biosimilarity.

Which commercial opportunities exist for teriflunomide excipient suppliers?

The strongest opportunities are in enabling technologies that reduce manufacturing cost or improve product robustness.

1. Low-cost generic tablet platforms

Excipient suppliers can offer validated direct-compression or dry-granulation systems optimized for low-dose, poorly soluble drugs. The value proposition is shorter development time, fewer process changes, and improved content uniformity.

2. Pediatric-friendly formulations

The pediatric indication creates an opportunity for dispersible, orally disintegrating, mini-tablet, or sprinkle presentations. These products may require additional regulatory work and cannot assume automatic substitution for the approved tablet. Taste masking, dose flexibility, and swallowability are important design factors.

3. Geographic formulation adaptation

Excipient selection must account for local availability, pharmacopeial status, climate, and regulatory expectations. Humid markets may favor lower-moisture excipient systems and stronger moisture-barrier coatings. Markets with lactose intolerance concerns may favor lactose-free formulations, although lactose in a small tablet is generally not a decisive commercial barrier.

4. Dissolution-enhancing platforms

Spray-dried dispersions, nanocrystals, and surfactant-assisted systems may be suitable for line extensions or differentiated products. Their commercial value depends on whether they produce clinically meaningful benefits or merely increase manufacturing cost.

5. Manufacturing and process IP

Process-focused opportunities include:

• Continuous blending for low-dose content uniformity.
• Dry granulation for solvent-free processing.
• Controlled micronization.
• High-shear granulation with optimized binder addition.
• Film-coating systems that improve moisture protection.
• Automated in-process control for tablet weight, hardness, and dissolution.

How strong is the teriflunomide patent estate for a new entrant?

The estate is materially less protective for a conventional generic entrant than it was before generic approvals. A new entrant should focus on freedom to operate around residual method, formulation, and process claims rather than assume that expired compound protection eliminates all risk.

Risk area	Assessment for a conventional generic
Active ingredient	Lower risk after core exclusivity expiration, subject to jurisdiction
Immediate-release tablet	Moderate risk from residual composition or process claims
Pediatric formulation	Potentially higher risk if using a novel dosage form
Amorphous dispersion	Higher risk because of solid-form and composition claims
Nanocrystal product	Higher risk from particle-engineering patents
Manufacturing process	Depends on granulation, micronization, and purification routes
Biosimilar pathway	Not applicable
Orange Book strategy	Must be reviewed against current listed patents
Settlement restrictions	Must be checked for each historical ANDA agreement

What generic launch scenarios exist for teriflunomide?

The market supports three practical launch models.

Commodity generic

This model uses a conventional immediate-release tablet with low-cost excipients and a manufacturing process close to the reference product. It offers the lowest technical risk but faces the highest price pressure.

Differentiated generic

This model uses a lactose-free, pediatric-friendly, smaller, or easier-to-swallow presentation. It can support channel-specific pricing or improve access but may require additional development and regulatory work.

Technology-enabled product

This model uses a solid dispersion, nanocrystal, or specialized coating system to improve dissolution or stability. It may create patentable know-how but has the greatest cost and regulatory burden.

For most manufacturers, the commodity generic is the rational base case. Excipient differentiation becomes commercially attractive only when it lowers total cost of goods, enables a specific geographic market, or supports a clinically relevant dosage-form improvement.

Key Takeaways

• Teriflunomide is a small-molecule, once-daily immediate-release tablet, not a biologic.
• A conventional lactose- or cellulose-based formulation with a robust disintegrant system is the lowest-risk commercial platform.
• The main technical issue is dissolution and low-dose content uniformity, not controlled release.
• Micronization, wetting control, and optimized disintegration are more commercially practical than complex lipid or nanotechnology systems for standard generics.
• FDA-approved generic competition has reduced the value of an undifferentiated teriflunomide tablet.
• Excipient patents are most valuable when supported by measurable improvements in dissolution, stability, content uniformity, or manufacturability.
• Pediatric, lactose-free, mini-tablet, and orally disintegrating formats offer the clearest line-extension opportunities.
• Residual Orange Book patents, method-of-use claims, process patents, and settlement terms remain relevant to freedom-to-operate analysis.
• A conventional generic has lower technical risk but faces severe price competition. A differentiated product has greater commercial upside but also higher regulatory and IP exposure.

FAQs

Can teriflunomide be formulated as an orally disintegrating tablet?

Yes, but the formulation would require control of taste, disintegration time, friability, moisture sensitivity, and dose uniformity. It would be a differentiated dosage form rather than a simple substitution for the standard film-coated tablet.

Is lactose necessary in a teriflunomide tablet?

No. Lactose can be replaced with microcrystalline cellulose, mannitol, starch, or other suitable diluents. A lactose-free formulation may support specific patient or market preferences, but it must still meet dissolution and bioequivalence requirements.

Which excipient is best for improving teriflunomide dissolution?

No single excipient is universally best. Crospovidone, croscarmellose sodium, sodium starch glycolate, and low-level wetting agents should be compared using dissolution, stability, tablet hardness, and scale-up data.

Can a teriflunomide formulation receive separate patent protection?

Yes. A formulation may be patentable if it contains a novel and non-obvious composition or process with a defensible technical effect. Conventional excipient combinations without unexpected performance are less likely to provide strong protection.

Does a new teriflunomide excipient system require a biosimilar application?

No. Teriflunomide is a small molecule. A conventional generic tablet uses the ANDA pathway, while a materially different product may require a separate regulatory strategy depending on the dosage form, claims, and clinical profile.

References

1. U.S. Food and Drug Administration. (2024). Aubagio (teriflunomide) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Patent and Trademark Office. (n.d.). U.S. Patent No. 7,632,938: Teriflunomide-related pharmaceutical composition and use. USPTO.

4. U.S. Food and Drug Administration. (2012). FDA approves Aubagio to treat multiple sclerosis. FDA.